VIVUS, Inc. Announces Third Quarter Financial Results Conference Call
MOUNTAIN VIEW, Calif., Oct. 24 /PRNewswire-FirstCall/ -- VIVUS, Inc. today announced that the company will host a conference call at 4:00 p.m. Eastern Time on Wednesday, October 26, 2005 to discuss its accomplishments and financial results for the third quarter ended September 30, 2005. The conference call information is as follows:
Conference Call Toll free dial-in number: 877-660-0983 Conference ID #: 1836976 Webcast A live webcast and 30 day archive of the call can be accessed at www.vivus.com. A telephone replay of the conference call will be available for 24 hours beginning October 26th at approximately 6:00 p.m. Eastern Time by dialing 800-642-1687 Domestically and entering reservation number 1836976. About VIVUS
VIVUS, Inc. is a pioneer in the research and development of proprietary products to restore sexual function for women and men. VIVUS' current product pipeline includes four investigational products in late stage clinical development. For women, VIVUS has initiated a Phase 2B program with ALISTA(TM) for female sexual arousal disorder and a Phase 3 program for Evamist(TM) for the alleviation of menopausal symptoms. Testosterone MDTS(R) for the treatment of hypoactive sexual desire disorder has completed Phase 2 development. The MDTS system is a patented new-generation, transdermal drug delivery technology that delivers drugs through the skin. For men, VIVUS is developing avanafil for erectile dysfunction, which has completed Phase 2 development. VIVUS currently markets MUSE(R) (alprostadil) suppository for the treatment of erectile dysfunction in the U.S. and internationally through distributors. For more information on clinical trials and products, please visit the Company's web site at www.vivus.com.
For more information: VIVUS, Inc. Timothy E. Morris 650-934-5200VIVUS, Inc.
CONTACT: Timothy E. Morris of VIVUS, Inc., +1-650-934-5200
Web site: http://www.vivus.com/